Insulin Biosimilars Portfolio
Diabetes Mellitus
Approved/CommercialActive
Key Facts
About GEROPHARM
GEROPHARM has evolved from a domestic player into a significant, vertically integrated biotech company and the market leader for insulin in Russia. Its strategy is built on mastering complex biotechnologies, particularly for insulin and biosimilars, and expanding its international footprint through exports and local production partnerships. With over $160 million invested in R&D and innovation in the past decade and two major manufacturing sites, the company is positioned to capitalize on import substitution policies and growing demand in emerging markets.
View full company profileTherapeutic Areas
Other Diabetes Mellitus Drugs
| Drug | Company | Phase |
|---|---|---|
| Insulin Aspart Biosimilar | USV Biologics Division | Commercial |
| Sirolimus-Coated Balloon (SCB) - DEDICATE Registry | Concept Medical | Registry |
| Gensulin (Human Insulin) | Bioton | Approved |
| Biosimilar Insulin Glargine | Wockhardt | Launched |
| Biosimilar Insulin Aspart | Wockhardt | Launched |
| Human Insulin | EVA Pharma | Approved |
| Insulin Glargine | Biomm | Approved |
| Insulin Analog Formulations | RPG Life Sciences | ANDA Filed/Development |